“Postpartum Depression Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Postpartum Depression Market.
The Postpartum Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Postpartum Depression Pipeline Report:
Companies across the globe are diligently working toward developing novel Postpartum Depression treatment therapies with a considerable amount of success over the years.
Postpartum Depression companies working in the treatment market are SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others, are developing therapies for the Postpartum Depression treatment
Emerging Postpartum Depression therapies in the different phases of clinical trials are- Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others are expected to have a significant impact on the Postpartum Depression market in the coming years.
In June 2025, Lipocine began dosing participants in its two-arm, blinded, randomized Phase III trial of LPCN 1154, an oral brexanolone therapy for postpartum depression (PPD). The trial launch follows feedback from the U.S. Food and Drug Administration (FDA), which permitted the study to be conducted in an outpatient setting without requiring continuous medical monitoring by healthcare providers. Lipocine plans to use the results from this trial to support a New Drug Application (NDA) submission, targeted for mid-2026.
In March 2025, Lipocine announced the start of a randomized Phase III clinical trial for LPCN 1154, an oral brexanolone formulation being developed to treat postpartum depression (PPD). This trial launch follows pharmacokinetic bridging data comparing LPCN 1154 with the reference drug. Lipocine expects to administer the first dose to a participant in the second quarter of this year as part of the Phase III trial.
Postpartum Depression Overview
Postpartum depression is a type of mood disorder that affects women after childbirth. It involves feelings of extreme sadness, anxiety, fatigue, and emotional distress that interfere with a mother’s ability to care for herself or her baby. Unlike the “baby blues,” which typically resolve within a few days, postpartum depression can last for weeks or months if untreated. Causes include hormonal changes, emotional stress, lack of sleep, and personal or family history of depression. Treatment may involve counseling, antidepressant medications, and support groups to help manage symptoms and promote recovery.
Get a Free Sample PDF Report to know more about Postpartum Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight
Emerging Postpartum Depression Drugs Under Different Phases of Clinical Development Include:
Zuranolone(SAGE-217): SAGE Therapeutics
BRII-296: Brii Biosciences Limited
RE104: Reunion Neuroscience
GH001: GH Research
Brexanolone: Sage Therapeutics
aripiprazole: Bristol-Myers Squibb
Postpartum Depression Route of Administration
Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Postpartum Depression Molecule Type
Postpartum Depression Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Postpartum Depression Pipeline Therapeutics Assessment
Postpartum Depression Assessment by Product Type
Postpartum Depression By Stage and Product Type
Postpartum Depression Assessment by Route of Administration
Postpartum Depression By Stage and Route of Administration
Postpartum Depression Assessment by Molecule Type
Postpartum Depression by Stage and Molecule Type
DelveInsight’s Postpartum Depression Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Postpartum Depression product details are provided in the report. Download the Postpartum Depression pipeline report to learn more about the emerging Postpartum Depression therapies
Some of the key companies in the Postpartum Depression Therapeutics Market include:
Key companies developing therapies for Postpartum Depression are – Pfizer Inc., Lilly (Eli Lilly and Company), GSK plc., Merck & Co., Inc, Sage Therapeutics, Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd., and others.
Postpartum Depression Pipeline Analysis:
The Postpartum Depression pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Postpartum Depression with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression Treatment.
Postpartum Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Postpartum Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postpartum Depression market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Postpartum Depression drugs and therapies
Postpartum Depression Pipeline Market Drivers
ZULRESSO starts working within 2–3 days of the administration, drastically improving the response rates compared to conventional therapies
Therapies like BRII-296 and LPCN-1154 are in early stages of clinical development and their approval in future can help the PPD therapeutic market grow tremendously.
Postpartum Depression Pipeline Market Barriers
Limited therapies are available for treating and diagnosing Postpartum Depression, thus providing profitable opportunities for emerging therapies
Increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives alucrative opportunity for the Postpartum Depression market
Scope of Postpartum Depression Pipeline Drug Insight
Coverage: Global
Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others
Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others
Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression emerging therapies
Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers
Request for Sample PDF Report for Postpartum Depression Pipeline Assessment and clinical trials
Table of Contents
1. Postpartum Depression Report Introduction
2. Postpartum Depression Executive Summary
3. Postpartum Depression Overview
4. Postpartum Depression- Analytical Perspective In-depth Commercial Assessment
5. Postpartum Depression Pipeline Therapeutics
6. Postpartum Depression Late Stage Products (Phase II/III)
7. Postpartum Depression Mid Stage Products (Phase II)
8. Postpartum Depression Early Stage Products (Phase I)
9. Postpartum Depression Preclinical Stage Products
10. Postpartum Depression Therapeutics Assessment
11. Postpartum Depression Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Postpartum Depression Key Companies
14. Postpartum Depression Key Products
15. Postpartum Depression Unmet Needs
16 . Postpartum Depression Market Drivers and Barriers
17. Postpartum Depression Future Perspectives and Conclusion
18. Postpartum Depression Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
